Literature DB >> 22101277

The mitochondrial protein C1qbp promotes cell proliferation, migration and resistance to cell death.

Allison M McGee1, Diana L Douglas, Yayun Liang, Salman M Hyder, Christopher P Baines.   

Abstract

Complement 1q-Binding Protein (C1qbp) is a mitochondrial protein reported to be upregulated in cancer. However, whether C1qbp plays a tumor suppressive or tumorigenic role in the progression of cancer is controversial. Moreover, the exact effects of C1qbp on cell proliferation, migration, and death/survival have not been definitely proven. To this end, we comprehensively examined the effects of C1qbp on mitochondrial-dependent cell death, proliferation, and migration in both normal and breast cancer cells using genetic gain- and loss-of-function approaches. In normal fibroblasts, overexpression of C1qbp protected the cells against staurosporine-induce apoptosis, increased proliferation, decreased cellular ATP, and increased cell migration in a wound-healing assay. In contrast, the opposite effects were observed in fibroblasts depleted of C1qbp by RNA interference. C1qbp expression was found to be markedly elevated in 4 different human breast cancer cell lines as well as in ductal and adenocarcinoma tumors from breast cancer patients. Stable knockdown of C1qbp by shRNA in the aggressive MDA-MB-231 breast cancer cell line greatly reduced cell proliferation, increased ATP levels, and decreased cell migration compared to control shRNA-transfected cells. Moreover, C1qbp knockdown elicited a significant increase in doxorubicin-induced apoptosis in the MDA-MB-231 cells. Finally, C1qbp upregulation was not restricted to breast cancer cells and tumors, as levels of C1qbp were also found to be significantly elevated in both human lung and colon cancer cell lines and carcinomas. Together, these results establish a pro-tumor, rather than anti-tumor, role for C1qbp, and indicate that C1qbp could serve as a molecular target for cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101277      PMCID: PMC3272292          DOI: 10.4161/cc.10.23.18287

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  35 in total

Review 1.  Mitochondria as subcellular targets for clinically useful anthracyclines.

Authors:  K Jung; R Reszka
Journal:  Adv Drug Deliv Rev       Date:  2001-07-02       Impact factor: 15.470

Review 2.  gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection.

Authors:  B Ghebrehiwet; B L Lim; R Kumar; X Feng; E I Peerschke
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

3.  HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells.

Authors:  Giuseppina Comito; Maura Calvani; Elisa Giannoni; Francesca Bianchini; Lido Calorini; Eugenio Torre; Cristina Migliore; Silvia Giordano; Paola Chiarugi
Journal:  Free Radic Biol Med       Date:  2011-06-12       Impact factor: 7.376

4.  Characterization of the binding of purified human C1q to heart mitochondrial membranes.

Authors:  S B Storrs; W P Kolb; R N Pinckard; M S Olson
Journal:  J Biol Chem       Date:  1981-11-10       Impact factor: 5.157

5.  The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein.

Authors:  J Dedio; W Jahnen-Dechent; M Bachmann; W Müller-Esterl
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

6.  Human p32, interacts with B subunit of the CCAAT-binding factor, CBF/NF-Y, and inhibits CBF-mediated transcription activation in vitro.

Authors:  Chandrani Chattopadhyay; David Hawke; Ryuji Kobayashi; Sankar N Maity
Journal:  Nucleic Acids Res       Date:  2004-07-08       Impact factor: 16.971

7.  Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells.

Authors:  Daniel B Rubinstein; Alexei Stortchevoi; Michael Boosalis; Raheela Ashfaq; Berhane Ghebrehiwet; Ellinor I B Peerschke; Fabien Calvo; Thierry Guillaume
Journal:  Int J Cancer       Date:  2004-07-10       Impact factor: 7.396

8.  Tissue factor pathway inhibitor-2 (TFPI-2) recognizes the complement and kininogen binding protein gC1qR/p33 (gC1qR): implications for vascular inflammation.

Authors:  Ellinor I B Peerschke; Ramona J Petrovan; Berhane Ghebrehiwet; Wolfram Ruf
Journal:  Thromb Haemost       Date:  2004-10       Impact factor: 5.249

9.  Physical and functional interaction between BH3-only protein Hrk and mitochondrial pore-forming protein p32.

Authors:  J Sunayama; Y Ando; N Itoh; A Tomiyama; K Sakurada; A Sugiyama; D Kang; F Tashiro; Y Gotoh; Y Kuchino; C Kitanaka
Journal:  Cell Death Differ       Date:  2004-07       Impact factor: 15.828

10.  Retargeting of the mitochondrial protein p32/gC1Qr to a cytoplasmic compartment and the cell surface.

Authors:  H C van Leeuwen; P O'Hare
Journal:  J Cell Sci       Date:  2001-06       Impact factor: 5.285

View more
  33 in total

1.  Elevated expression of HABP1 is correlated with metastasis and poor survival in breast cancer patients.

Authors:  Ming Niu; Shanshan Sun; Guoqiang Zhang; Yashuang Zhao; Da Pang; Yanbo Chen
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Microarray analysis of differential gene expression profiles in blood cells of naturally BLV-infected and uninfected Holstein-Friesian cows.

Authors:  P Brym; S Kamiński
Journal:  Mol Biol Rep       Date:  2016-11-03       Impact factor: 2.316

3.  Subcellular proteomics reveals a role for nucleo-cytoplasmic trafficking at the DNA replication origin activation checkpoint.

Authors:  Claire M Mulvey; Slavica Tudzarova; Mark Crawford; Gareth H Williams; Kai Stoeber; Jasminka Godovac-Zimmermann
Journal:  J Proteome Res       Date:  2013-02-06       Impact factor: 4.466

4.  High expression of apoptosis-inducing factor, mitochondrion-associated 3 (AIFM3) in human cholangiocarcinoma.

Authors:  Daraporn Chua-On; Tanakorn Proungvitaya; Anchalee Techasen; Temduang Limpaiboon; Sittiruk Roytrakul; Sopit Wongkham; Chaisiri Wongkham; Ongart Somintara; Sakkarn Sungkhamanon; Siriporn Proungvitaya
Journal:  Tumour Biol       Date:  2016-07-29

5.  Characterization of antiproliferative potential and biological targets of a copper compound containing 4'-phenyl terpyridine.

Authors:  Ana Soraia Mendo; Sara Figueiredo; Catarina Roma-Rodrigues; Paula A Videira; Zhen Ma; Mário Diniz; Miguel Larguinho; Pedro M Costa; João C Lima; Armando J L Pombeiro; Pedro V Baptista; Alexandra R Fernandes
Journal:  J Biol Inorg Chem       Date:  2015-06-16       Impact factor: 3.358

6.  C1QBP is upregulated in colon cancer and binds to apolipoprotein A-I.

Authors:  Kun Kim; Min-Jeong Kim; Kyung-Hee Kim; Sun-A Ahn; Jong Heon Kim; Jae Youl Cho; Seung-Gu Yeo
Journal:  Exp Ther Med       Date:  2017-03-21       Impact factor: 2.447

Review 7.  Targeting cancer cell mitochondria as a therapeutic approach.

Authors:  Shijun Wen; Daqian Zhu; Peng Huang
Journal:  Future Med Chem       Date:  2013-01       Impact factor: 3.808

Review 8.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

9.  Protein profiling of SH-SY5Y neuroblastoma cells: The effect of rhein.

Authors:  Zuzana Cockova; Hana Ujcikova; Petr Telensky; Jiri Novotny
Journal:  J Biosci       Date:  2019-09       Impact factor: 1.826

10.  [Value of CHCHD2 as a potential marker of non-small cell lung cancer: analysis of 60 cases].

Authors:  Rui Xu; Sheng-Yu Wang; Li Wang; Man-Xiang Li; Yang Yao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.